This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Chinook Therapeutics 관리

관리 기준 확인 2/4

Chinook Therapeutics CEO는 Eric Dobmeier, Apr2019 에 임명되었습니다 의 임기는 4.33 년입니다. 총 연간 보상은 $ 4.84M, 12.4% 로 구성됩니다. 12.4% 급여 및 87.6% 보너스(회사 주식 및 옵션 포함). 는 € 11.11M 가치에 해당하는 회사 주식의 0.42% 직접 소유합니다. 11.11M. 경영진과 이사회의 평균 재임 기간은 각각 2.2 년과 3.5 년입니다.

주요 정보

Eric Dobmeier

최고 경영자

US$4.8m

총 보상

CEO 급여 비율	12.4%
CEO 임기	4.3yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	2.2yrs
이사회 평균 재임 기간	3.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Eric Dobmeier 의 보수는 Chinook Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2023	n/a	n/a	-US$246m
Mar 31 2023	n/a	n/a	-US$216m
Dec 31 2022	US$5m	US$601k	-US$188m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$92m
Mar 31 2022	n/a	n/a	-US$97m
Dec 31 2021	US$4m	US$547k	-US$103m
Sep 30 2021	n/a	n/a	-US$160m
Jun 30 2021	n/a	n/a	-US$149m
Mar 31 2021	n/a	n/a	-US$114m
Dec 31 2020	US$6m	US$438k	-US$82m

보상 대 시장: Eric 의 총 보상 ($USD 4.84M )은 German 시장( $USD 1.90M ).

보상과 수익: 회사가 수익성이 없는 동안 Eric 의 보상이 증가했습니다.

CEO

Eric Dobmeier (54 yo)

4.3yrs

테뉴어

US$4,841,699

보상

Mr. Eric L. Dobmeier, J.D., has been an Independent Director at Structure Therapeutics Inc. since December 2022. He is the President, Chief Executive Officer and Director of Chinook Therapeutics, Inc. sinc...

리더십 팀

이름	위치	테뉴어	보상	소유권
Eric Dobmeier	President	4.3yrs	US$4.84m	0.42% € 11.1m
Tom Frohlich	Chief Operating Officer	2.2yrs	US$2.02m	0.21% € 5.6m
Andrew King	Chief Scientific Officer	2.2yrs	US$2.23m	0.027% € 706.8k
Eric Bjerkholt	Chief Financial Officer	2.8yrs	데이터 없음	0.054% € 1.4m
Sukhi Thethy	Senior Vice President of Finance & Accounting	less than a year	데이터 없음	데이터 없음
Noopur Liffick	Senior Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Kirk Schumacher	Senior VP & General Counsel	no data	데이터 없음	데이터 없음
Jodi Jamieson	Senior Vice President of Human Resources	no data	데이터 없음	데이터 없음
Alan Glicklich	Executive Officer	3.3yrs	US$2.41m	0.011% € 291.2k
Delphine Imbert	Senior Vice President of CMC & Technical Operations	2.3yrs	데이터 없음	데이터 없음
Charlotte Jones-Burton	Senior Vice President of Product Development & Strategy	1.6yrs	데이터 없음	데이터 없음
Andrew Oxtoby	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음

2.2yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: 290A 의 관리팀은 경험 ( 2.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Eric Dobmeier	President	4.3yrs	US$4.84m	0.42% € 11.1m
Michelle Griffin	Independent Director	2.8yrs	US$233.60k	0.0046% € 121.9k
Srinivas Akkaraju	Independent Director	4.1yrs	US$227.60k	0.0046% € 121.9k
William Greenman	Independent Director	13.2yrs	US$233.10k	0.033% € 872.4k
Mahesh Krishnan	Independent Director	1.4yrs	US$451.98k	0.0018% € 47.2k
Jerel Davis	Independent Lead Director	4.7yrs	US$244.60k	0.62% € 16.5m
Robert Azelby	Independent Director	less than a year	데이터 없음	0% € 0
Dolca Thomas	Independent Director	2.8yrs	US$217.60k	0.019% € 490.7k

3.5yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 이사회: 290A 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.

This company listing is no longer active

Chinook Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Independent Lead Director recently sold €5.6m worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

President recently sold €175k worth of stock

Independent Director recently bought €212k worth of stock

High number of new directors

President recently bought €61k worth of stock

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

First quarter 2023 earnings released: US$0.85 loss per share (vs US$0.54 loss in 1Q 2022)

Independent Lead Director recently sold €5.6m worth of stock

Full year 2022 earnings released: US$2.87 loss per share (vs US$2.26 loss in FY 2021)

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

President recently sold €175k worth of stock

Third quarter 2022 earnings released: US$0.83 loss per share (vs US$0.69 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.83 loss per share (vs US$0.69 loss in 3Q 2021)

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Independent Director recently bought €212k worth of stock

Second quarter 2022 earnings released: US$0.61 loss per share (vs US$0.97 loss in 2Q 2021)

High number of new directors

President recently bought €61k worth of stock

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

First quarter 2022 earnings released: US$0.54 loss per share (vs US$0.88 loss in 1Q 2021)

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

President recently bought €101k worth of stock

Sairopa B.V., entered into an agreement to acquire non-renal assets of Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell Microcap Growth Index

Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress

Chinook Therapeutics, Inc. announced delayed annual 10-K filing

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 Align Study of Atrasentan for Patients with Iga Nephropathy

Chinook Therapeutics, Inc. and Evotec SE Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Chk-336 for Treatment of Primary Hyperoxaluria

Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities

President recently bought €53k worth of stock

Chinook Therapeutics Announces Appointment of Eric Bjerkholt as Chief Financial Officer

Chinook Therapeutics, Inc. Provides Business Update

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령